Wang Xing, Zhang Juan, Zhou Liang, Lu Peng, Zheng Zhi-Gang, Sun Wei, Wang Jian-Lin, Yang Xi-Sheng, Li Xiao-Lei, Xia Ning, Zhang Ning, Dou Ke-Feng
Department of Hepatobiliary Surgery, Xijing Hospital, The Fourth Military Medical University Xi'an 710032, Shannxi, China.
Department of Stomatology, 44 Hospital of PLA Guiyang, Guizhou 550009, China.
Int J Clin Exp Pathol. 2015 Feb 1;8(2):1466-78. eCollection 2015.
MicroRNAs (miRNAs) are associated with human carcinogenesis and tumor development. Moreover, serum miRNAs can reflect the level of tissue miRNAs and be potential tumor markers. Serum microRNA-21 (miR-21) is overexpressed in many human cancers including hepatocellular carcinoma (HCC). However, how serum miR-21 changes during the HCC formation and whether miR-21 plays a regulatory role in this whole process are unknown. The current study evaluated the prognostic and diagnostic potential of serum miR-21 in HCC patients. Next, we established a HCC rat model and collected the blood and liver tissues at regular time points. AFP from the serum, RNA from the serum and liver tissues were collected and quantified separately. The results revealed that tissue and serum miR-21 was upregulated significantly in the groups of cirrhosis, early and advanced HCC compared with normal and fibrosis groups. The AFP levels were increased in early and advanced HCC compared with other groups. Then, the changes of miR-21 downstream proteins (i.e., programmed cell death 4 [PDCD4] and phosphatase and tensin homolog [PTEN]) in the liver tissues were measured. PDCD4 and PTEN expression was decreased gradually after tumor induction and negatively correlated with miR-21 expression. All these results suggested that serum miR-21 was associated with the prognosis of HCC; the changes in serum miR-21 were earlier and more accurately reflected the pathogenesis of HCC than AFP; therefore, it could be used as an early diagnostic marker for HCC. Our in vivo experiments further confirmed that miR-21 plays an important role in promoting the occurrence and development of HCC by regulating PDCD4 and PTEN.
微小RNA(miRNA)与人类癌症发生及肿瘤发展相关。此外,血清miRNA可反映组织miRNA水平,且有可能成为肿瘤标志物。血清微小RNA-21(miR-21)在包括肝细胞癌(HCC)在内的多种人类癌症中均呈过表达。然而,血清miR-21在HCC形成过程中如何变化,以及miR-21在这一整个过程中是否发挥调节作用尚不清楚。当前研究评估了血清miR-21在HCC患者中的预后及诊断潜力。接下来,我们建立了HCC大鼠模型,并在规定时间点采集血液和肝脏组织。分别收集并定量血清中的甲胎蛋白(AFP)、血清及肝脏组织中的RNA。结果显示,与正常组和纤维化组相比,肝硬化组、早期和晚期HCC组的组织及血清miR-21显著上调。与其他组相比,早期和晚期HCC组的AFP水平升高。然后,检测肝脏组织中miR-21下游蛋白(即程序性细胞死亡4 [PDCD4]和磷酸酶及张力蛋白同源物[PTEN])的变化。肿瘤诱导后,PDCD4和PTEN表达逐渐降低,且与miR-21表达呈负相关。所有这些结果表明,血清miR-21与HCC的预后相关;血清miR-21的变化比AFP更早且更准确地反映HCC的发病机制;因此,它可作为HCC的早期诊断标志物。我们的体内实验进一步证实,miR-21通过调节PDCD4和PTEN在促进HCC的发生和发展中发挥重要作用。